###### Strengths and limitations of this study

-   Two publicly available data sets from the British National Diet and Nutrition Surveys (NDNS) were used to investigate the association between dietary intake of B~12~ and folate and their blood concentrations in women of childbearing age.

-   The women sampled in the surveys were representative of UK adults; therefore, the findings can be generalised to the wider UK population.

-   Information about the participants, including demographics, dietary intakes, blood results and anthropometry, was used for detailed analysis of the outcomes of interest.

-   The availability of two separate NDNS data sets allowed comparison of micronutrient intakes over the last 15 years in young women.

-   Blood micronutrient concentrations were not analysed in the more recent survey. Therefore, the associations observed in the first survey could not be replicated.

Introduction {#s1}
============

Vitamin B~12~ (B~12~), also known as cobalamin, is a micronutrient essential for cellular growth, differentiation and development.[@R1] Along with folate, B~12~ is necessary for the synthesis of DNA, RNA, lipids and protein, and an essential step in this process is the conversion of homocysteine (Hcy) to methionine.[@R2] Therefore, a deficiency of either B~12~ or folate leads to increased Hcy which can have significant clinical implications such as cardiovascular disease and atherosclerosis in adults.[@R3] [@R4]

During pregnancy, low circulating levels of B~12~ or folate have been associated with complications such as neural tube defects (NTDs),[@R5] spontaneous abortion,[@R6] premature birth[@R7] and possibly low birth weight.[@R8] Mandatory folic acid fortification in North America has resulted in reduction of NTD by over 40% in the last 10 years,[@R9] but there has been a tripling of the condition attributable to B~12~ deficiency during the same time frame in this population.[@R10] Maternal hyperhomocysteinemia has been linked to early pregnancy losses,[@R11] pre-eclampsia[@R12] and small for gestational age babies.[@R13] Although the exact mechanisms are not known, some of these effects may be mediated by vascular compromise to the fetus and insufficient placental development which occurs in the early embryonic period.[@R14] As around half of the pregnancies are unplanned, even in developed countries,[@R15] there is increasing attention on optimising the nutrient status of women in the periconceptional period.

B~12~ deficiency is prevalent during pregnancy as shown by a large systematic review recently conducted by our group.[@R8] We showed that the rates were in the order of 20--30% in all three trimesters across the world, with particular high rates in studies from the Indian subcontinent, Eastern Mediterranean and South American regions.[@R16] A longitudinal study has shown that cobalamin levels can decrease by around 10--20% from preconception to the first and second trimesters, respectively.[@R19] However, there are no studies in the UK that assessed the B~12~ intake or circulating levels in women of reproductive age prior to conception.

The UK Department of Health (DOH) has stipulated that the Recommended Nutrient Intake (RNI) for B~12~ and folate in adults is 1.5 and 200 μg per day, respectively, with no different recommendations for women (pregnant or otherwise) and the elderly.[@R20] These recommendations were published in 1991 and state that the RNI for B~12~ 'represent the level of intake considered likely to be sufficient to meet the requirements of 97.5% of the group'.[@R21] The evidence for this RNI is from reports in the 1970s, which estimated the average requirement to prevent diet-related B~12~ deficiency and megaloblastic anaemia.[@R22] B~12~ deficiency in these studies was arbitrarily defined as \<150 pmol/L without use of any functional markers of B~12~ deficiency.[@R25] [@R26] Thus, there are little contemporary data to support how accurately the recommended intakes correlate with serum values of B~12~ and functional indicators such as Hcy. The primary aim of this study is to determine the serum B~12~, folate and Hcy status of women of childbearing age in the UK and to assess the correlation between estimated B~12~ intake and blood concentrations of B~12~ and Hcy using the data from two British National Diet and Nutrition Survey (NDNS) in 2000/2001 and 2008/2012. The secondary aim is to compare the nutritional intake between the two NDNS cohort to provide more recent data on B~12~ intake.

Methods {#s2}
=======

Subjects {#s2a}
--------

We used data collected from the two British NDNS between July 2000 and June 2001 and 2008--2012. The surveys provide detailed quantitative assessment of nutritional status and laboratory results of the participants. The methods used in the survey have previously been described in detail.[@R27] The samples were made up of randomly selected adults aged 19--64 years living in private households, who were representative of the UK adult population. Their selection was done by a multistage, stratified, probability sampling with postal sectors as first stage units. If there were more than one adult in the same household, one was selected randomly. Women who were pregnant or breast feeding were excluded.

The selection of the participants included in our analysis is provided in online [supplementary figure](#SM2){ref-type="supplementary-material"}s S1 and S2. For the first survey (2000/2001), the fieldwork was carried out over a 12-month period, with respondents being surveyed over four 3-month periods to account for seasonal variations in nutritional behaviour and content. Out of 3704 potentially eligible adults identified for the study, 299 women between 19 and 39 years of age (known as women of 'childbearing age' for the purpose of our analysis) with complete dietary and biomarker information were included in the final analysis. In an independent study,[@R30] no evidence of was found of non-response bias in this NDNS data.
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The second survey (2008/2012) consisted of 2424 adults of whom 395 were women of childbearing age. Unfortunately, blood samples were only obtained from 157 of these women (ie, 39.7% of all females aged 19--39 years). The main reasons for this low return of blood samples were 'no nurse visit', 'participant refused' and 'blood sample inapplicable'. Owing to the potential bias from a sample of women not representative of the larger NDNS cohort, we only included and compared the micronutrient intakes from the two surveys to assess the secular trend.

Assessment of dietary intake {#s2b}
----------------------------

This has been described in detail elsewhere.[@R27] Briefly, dietary assessment for each participant was done by a two-stage process: (1) two face-to-face interviews using computer-assisted personal interviewing methods, and (2) a 7-day dietary record using weighed food diaries. Each participant was provided with a set of Soehnle Quanta digital food scales and two recording diaries (for use at home and outside). Additional information was obtained about the use of medicines, vitamin and mineral supplements. Information provided in the food diaries was later used to determine nutrient intakes by linking to the Food Standards Agency nutrient database, which holds details for 56 nutrients for each of 6000 food codes.[@R27]

Laboratory methods {#s2c}
------------------

Venous blood samples were taken at the non-fasting state by trained phlebotomists in participants\' homes. Serum folate and B~12~ measurements were performed on the Abbott IMx semiautomated analyser, which uses microparticle enzyme immunoassay (MEIA) technology (z). Quality control consisted of an internal pooling of serum samples with each run for use as a drift control, and an external quality assessment by the UK National External Quality Assessment Service (NEQAS). Outlying results were defined as serum B~12~ level \>1000 pmol/L and serum folate \>60 nmol/L and were excluded. Plasma Hcy measurements were performed by the Abbott IMx assay on the IMx analyser. Quality control consisted of participation in an international external quality assessment scheme based in Denmark[@R31] and by the manufacturer\'s QV samples.

Statistical analysis {#s2d}
--------------------

Statistical analysis was performed with SPSS V.22.0 (IBM SPSS Statistics for Windows, Version 22.0 (program). Armonk, NY: IBM Corp, Released 2013). For continuous variables (eg, mean B~12~/folate intakes and levels between RNI threshold groups), the Student's t-test and for categorical variables (eg, B~12~ and folate deficiency rates), the χ^2^ test for independence or the Fisher\'s exact test was used. Stepwise multiple linear regression analysis with each of serum B~12~, folate and plasma Hcy as the dependent variable was done, with predictors entered or removed following the criteria: probability of F to enter ≤0.050, probability of F to remove ≥0.100. The regression models included the following covariates: age, body mass index (BMI), total cholesterol:high-density lipoprotein (TC:HDL) ratio, alcohol intake, smoking status, oral contraceptive use, vegan/vegetarian, serum folate and where appropriate daily folate intake (with supplements), daily B~12~ intake (with supplements) and serum B~12~ levels. Race was not included in the analysis as the majority of the participants (95%) were white. To determine the trend of B~12~ and Hcy across the spectrum of B~12~ intakes, we divided the cohort into quintiles of B~12~ intake. One-way analysis of variance (ANOVA) with Tukey\'s post hoc test was applied to compare the serum levels against the lowest quintile. Logistic regression was then done for incremental B~12~ intake thresholds of 0.25 μg to determine predictors of B~12~ deficiency and hyperhomocysteinemia. In order to estimate the prevalence of inadequate B~12~ intake in our population and observe how this was related to abnormal biomarker levels, we used the Estimated Average Requirement (EAR) cut-point method.[@R32] The EAR was calculated as 1.25 μg/day based on a coefficient of variation of 10% below the UK RNI.[@R25]

The definitions for micronutrient deficiencies were as follows: serum B~12~≤150 pmol/L,[@R33] serum folate ≤10 nmol/L[@R34] and red cell folate \<350 nmol/L.[@R34] The upper limit of normal for plasma Hcy in non-pregnant adults aged 15--65 has been variably defined as 12 µmol/L in non-pregnant adults with folic acid fortification or supplementation[@R35] and 15 µmol/L in those without fortification or supplementation, which applies to our population. However, Hcy levels above 10.7 µmol/L in women during preconception has been associated with pre-eclampsia, prematurity and very low birthweight infants if they become pregnant.[@R12] In addition, other experts recommend \<12 µmol/L for all adults.[@R36] Therefore, we have presented results for 12 and 15 µmol/L and stated these clearly throughout.

Results {#s3}
=======

From the NDNS 2000/01 cohort, 299 women of childbearing age had complete dietary and serum micronutrient level results. The demographics and clinical characteristics of these women are shown in [table 1](#BMJOPEN2016011247TB1){ref-type="table"}. Their mean age was 31.6 years and BMI 25.3 kg/m^2^. To determine how the B~12~/folate intakes women of childbearing age compared with older women from the same NDNS survey, we analysed these parameters in women aged 40--64 years. The younger women consumed significantly less B~12~ and folate (median 3.83 vs 5.16 and 237 vs 279 μg/day, respectively, p\<0.001 for both) and consisted of more vegetarians/vegans (8.7% vs 4.2%, p\<0.05) and less B~12~ supplement users (10.4% vs 16.2%, p\<0.05). Folic acid supplement use was the same (data not shown).

###### 

Demographics and B~12~ and folate intakes of women of childbearing age (NDNS 2000/2001 cohort)

  Female 19--39 years                       All subjects (n=299)
  ----------------------------------------- ----------------------
  Age (years)                               31.6±5.7
  BMI (kg/m^2^)                             25.4±5.2
  Obesity, n (%)                            46 (15.7)
  Current smokers, n (%)                    117 (39.1)
  Regular alcohol drinkers, n (%)           267 (89.3)
  Oral contraceptive use, n (%)             103 (34.4)
  Ethnicity, n (%)                          
   White                                    283 (94.6)
   Afro-Caribbean                           3 (1.0)
   Asian                                    8 (2.7)
   Other                                    5 (1.7)
  Vegetarians, n (%)                        26 (8.7)
  B~12~ supplement users, n (%)             31 (10.4)
  B~12~ intake, diet only (μg/day)          3.82 (2.75, 5.02)
  B~12~ intake, diet+supplements (μg/day)   3.83 (2.82, 5.20)
  Folic acid supplement users, n (%)        32 (10.7)
  Folate intake with supplements (μg/day)   237 (177, 315)

Continuous variables are mean±SD or median (IQR).

Categorical variables are n (%).

BMI, body mass index; NDNS, National Diet and Nutrition Surveys.

The blood levels of B~12~, folate and Hcy in women of childbearing age and according to categories of UK RNI for B~12~ intake (adequate/inadequate) are given in [table 2](#BMJOPEN2016011247TB2){ref-type="table"}. The median serum B~12~ concentration was 241 pmol/L. Overall, 12% of women were B~12~ deficient (\<150 pmol/L), despite the median B~12~ intake of the deficient women being nearly two times the UK RNI (2.96 μg/day; data not shown). In total, 3.7% of the surveyed population had B~12~\<150 pmol/L and Hcy\>12 µmol/L, with a significantly higher proportion having the combination of abnormalities when their estimated was lower than the UK RNI (9.1% vs 3.5%, p=0.001). There is evidence that B~12~ levels \<258 pmol/L may be indicative of B~12~ deficiency in certain individuals with concomitant elevation of Hcy and methylmalonic acid (MMA).[@R37] In total, 44.0% of women had B~12~ levels in this borderline range of 150--258 pmol/L. In this subgroup, mean Hcy levels were significantly higher than the group with B~12~\>258 pmol/L (10.4 vs 9.2 µmol/L, p=0.02) despite similar folate levels (21.4 vs 22.0 nmol/L, p=NS).

###### 

Comparison of B~12~, folate and plasma homocysteine concentrations in women according to the UK RNI for vitamin B~12~ intake

  Female 19--39 years                                All subjects         UK RNI (μg/day)     p value\*           
  -------------------------------------------------- -------------------- ------------------- ------------------- ---------
  Number (%)                                         299 (100)            11 (3.7)            288 (96.3)          
  B~12~ intake, diet only (μg/day)                   3.82 (2.75, 5.02)†   1.29 (0.64, 1.46)   3.86 (2.86, 5.09)   \<0.001
  B~12~ intake, diet+supplements (μg/day)            3.83 (2.82, 5.20)    1.29 (0.98, 1.46)   3.92 (2.88, 5.32)   \<0.001
  Serum B~12~ (pmol/L)                               241 (188, 324)       169 (153, 256)      244 (189, 325)      0.05
  B~12~ deficiency (\<150 pmol/L), n (%)             36 (12.0)            2 (18.2)            34 (11.8)           NS
  Serum folate (nmol/L)                              19.5 (14.1, 26.7)    14.3 (13.6, 21.3)   19.7 (14.2, 27.0)   NS
  Serum folate deficiency (\<10 nmol/L), n (%)       18 (6.1)             0 (0)               18 (6.3)            NS
  Red cell folate (nmol/L)                           584 (473.9, 750.6)   460 (372, 739)      585 (478, 751)      NS
  Red cell folate deficiency (\<350 nmol/L), n (%)   13 (4.4)             2 (18.2)            11 (3.8)            NS
  Hcy (μmol/L)                                       9.4 (9.1, 9.8)       11.9 (9.6, 14.3)    9.2 (7.8, 11.4)     \<0.05
  High Hcy (\>12 μmol/L), n (%)                      62 (21.2)            5 (50)              57 (20.1)           \<0.05
  High Hcy (\>15 μmol/L), n (%)                      24 (8.2)             2 (20)              22 (7.8)            NS

\*Comparison between lower and higher B~12~ intake groups. For categorical variables, Student's t-test was used (after log transformation); for continuous variables, Fisher's exact test was used.

†Median, 25--75th centile in parentheses (all such values).

Hcy, homocysteine; NS, not significant; UK RNI, UK Recommended Nutrient Intake.

The plasma Hcy concentrations were higher in the lower intake group (11.9 vs 9.2 µmol/L, p\<0.05) although hyperhomocysteinemia (Hcy\>12 µmol/L) was present in 20% of women with apparently adequate B~12~ intake ([table 2](#BMJOPEN2016011247TB2){ref-type="table"}). Serum and red cell folate deficiency rates were 6.1% and 4.4%, respectively, in the whole population. There were no differences in the folate deficiency rates between above and below the UK RNI B~12~ intake groups. In total, 34.4% of the women were taking the oral contraceptives and their B~12~ values were lower than those who were not (median 211.5 vs 267.5 pmol/L, p\<0.001).

In total, 8.7% of women in the whole cohort were vegetarian or vegan and their median dietary intake of B~12~ was non-significantly lower than non-vegetarians (2.95 vs 3.87 μg/day), while folate consumption in the former group was higher (see online [supplementary table](#SM1){ref-type="supplementary-material"} S1). Vegetarians had lower serum B~12~ concentrations (median 192 vs 248 pmol/L, p\<0.01) but their folate or Hcy concentrations did not vary significantly.
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###### 

Biochemical indices in vegetarian and vegan women of child-bearing age compared to non-vegetarians

 {#s3a}

### Predictors of B~12~, folate and Hcy {#s3a1}

There was a positive correlation between serum B~12~ values and daily B~12~ intake (Pearson\'s r=0.27, p\<0.001) ([figure 1](#BMJOPEN2016011247F1){ref-type="fig"}). Simple linear regression analyses of the predictors of B~12~, folate and Hcy are shown in [table 3](#BMJOPEN2016011247TB3){ref-type="table"}. After adjusting for the likely confounders, daily B~12~ and folic acid intakes were positive predictors of serum B~12~ (β=0.28, p\<0.001) and serum folate (β=0.33, p\<0.001), respectively. Along with age, serum B~12~, serum folate and B~12~ intake were independent predictors of Hcy, though it would appear that serum folate is strongest based on the value of the β coefficient ([table 3](#BMJOPEN2016011247TB3){ref-type="table"}).

###### 

Multiple linear regression analysis of predictors of serum B~12~, folate and homocysteine

  Variables                   Serum B~12~\*   Serum folate   Homocysteine\*                      
  --------------------------- --------------- -------------- ---------------- --------- -------- ---------
  Age                         --              NS             --               NS        0.18     0.001
  BMI                         --              NS             --               NS        --       NS
  Smoking                     --0.12          \<0.05         --               NS        --       NS
  Alcohol                     --              NS             --               NS        --       NS
  Oral contraceptive use      −0.29           \<0.001        0.11             \<0.05    --       NS
  TC:HDL ratio\*              --              NS             --               NS        --       NS
  Vegetarian or vegan diet    −0.18           \<0.01         --               NS        --       NS
  B~12~ supplement use        --              NS             Not included     NA        --       NS
  Daily B~12~ intake\*        0.28            \<0.001        Not included     NA        --0.16   0.001
  Folic acid supplement use   Not included    NA             0.18             \<0.01    --       NS
  Daily folate intake\*       Not included    NA             0.33             \<0.001   --       NS
  Serum B~12~\*                                              --               NS        −0.20    \<0.001
  Serum folate\*              --              NS                                        −0.35    \<0.001

\*Log transformed for statistical comparison.

--, Tested but not significant in the model;

BMI, body mass index; NA, not applicable; NS, not significant; TC:HDL, total cholesterol:high-density lipoprotein ratio.

![Correlation between daily B~12~ intake and serum B~12~ values. §Log transformed for statistical comparisons.](bmjopen2016011247f01){#BMJOPEN2016011247F1}

### Relationship between B~12~ intake and associated biomarkers {#s3a2}

In total, 5 out of 299 (1.7%) women consumed below the EAR of 1.25 μg/day, but none of them had B~12~ levels \<150 pmol/L. Conversely, in the 98.3% of women with 'adequate' EAR category for B~12~ consumption, 12.2% of them had serum levels below 150 pmol/L.

In order to determine the trend of blood B~12~ and Hcy concentrations with increasing intakes of B~12~, we divided the cohort in quintiles of B~12~ intake. The median levels in each quintile and biomarker values are represented in [figures 2](#BMJOPEN2016011247F2){ref-type="fig"}A, B. Women in quintiles 4 and 5 (median intake 4.9 and 7.1 μg/day, respectively) had significantly higher mean B~12~ and lower mean Hcy concentrations than quintile 1 (291 and 322 vs 229 pmol/L; 9.0 and 9.0 vs 11.4 µmol/L, respectively). Additionally, the Hcy levels appear to level off between quintiles 4 and 5, suggesting that increasing intakes above 5 μg/day is unlikely to provide higher B~12~ at the tissue level ([figure 2](#BMJOPEN2016011247F2){ref-type="fig"}B). To confirm this, we performed logistic regression to determine the intake threshold at which the odds of hyperhomocysteinemia would reduce significantly after correcting for confounders. Using 0.25 μg increments, a threshold of 4.75 μg/day significantly reduced the odds of Hcy\>12 µmol/L (adjusted OR (AOR) 0.35, 95% CI 0.14 to 0.88). When serum B~12~ was added to the model, the significance was lost, suggesting that the influence of dietary B~12~ intake on circulating Hcy is mediated through serum B~12~ values in a folate-replete population (data not shown).

![Relationship between B~12~ intake in quintiles and (A) mean serum B~12~ and (B) mean plasma homocysteine concentrations. Mean±SEM values are plotted against the median B~12~ intake in each quintile. One-way analysis of variance (ANOVA) test used to compare the means between the quintiles (after log transformation) and Tukey's post hoc analysis done. Mean biomarker levels differed as compared with quintile 1 as follows: \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001.](bmjopen2016011247f02){#BMJOPEN2016011247F2}

### Micronutrient intake: comparisons between NDNS 2000/2001 and 2008/2012 data {#s3a3}

Comparison of the mean nutrient intake among young women between the two surveys is shown in [table 4](#BMJOPEN2016011247TB4){ref-type="table"}. The proportion of women consuming below the UK RNI for folate increased in the more recent survey (44% vs 33%, p\<0.01) and median intake levels fell by 14% (206 vs 235 pmol/L, p\<0.001). There were no significant differences in the B~12~ intake values.

###### 

Comparison between folic acid and B~12~ intakes between the NDNS 2000/2001 and 2008/2011 cohorts

  Female 19--39 years                      NDNS 2000/2001 cohort   NDNS 2008/2011 cohort
  ---------------------------------------- ----------------------- ----------------------------
  Number                                   299                     395
  Folic acid supplement users, n (%)       32 (10.7)               12 (3.0)\*\*\*,†
  Folate intake, diet only (μg/day)        234.9 (175.7, 302.7)‡   205.8 (162.3, 261.2)\*\*\*
  n (%) consuming below UK RNI of folate   99 (33.1)               173 (43.8)\*\*
  B~12~ supplement users, n (%)            31 (10.4)               33 (8.4)
  B~12~ intake, diet only (μg/day)         3.82 (2.75, 5.01)       3.78 (2.64, 4.84)
  n (%) consuming below UK RNI of B~12~    11 (3.7)                24 (6.1)

Significance: \*\*p\<0.01; \*\*\*p\<0.001

†p Values from independent-samples t-test for continuous variables (after log transformation) or χ^2^ test for categorical variables.

‡Median, 25--75th centile in parentheses (all such values).

UK RNI, UK Recommended Nutrient Intake; NDNS, National Diet and Nutrition Survey.

Discussion {#s4}
==========

Our study shows contemporary data of B~12~ and folate intakes and serum levels in population-based nutritional surveys involving women of childbearing age, who are representative of the UK population. The key findings are that, despite an apparent adequate daily intake of B~12~, a high proportion of women have B~12~ deficiency and hyperhomocysteinemia.

Optimum B~12~ intake and biomarker levels {#s4a}
-----------------------------------------

Our data showed positive correlation between B~12~ intake and blood levels with a trend of increasing B~12~ concentration even in intakes up to 7 μg/day, although the corresponding reductions in Hcy levels level off around the intake of 5--7 μg/day. Additionally, the consumption of around 4.75 μg/day was independently associated with a decrease in the odds of hyperhomocysteinemia. Our findings are supportive of the dose--response relationship between intake and blood levels of B~12~ found previously, which showed doubling B~12~ intakes would increase B~12~ concentrations by around 10%.[@R38]

A daily intake of 4--10 μg has been suggested by other studies to stabilise levels of B~12~, Hcy and the associated MMA in adults,[@R39] [@R40] but more evidence is needed before extrapolating these figures to women of childbearing age due to the different requirements and implications should they become pregnant. In a randomised controlled trial where all subjects consumed 8.6 μg/day of B~12~, pregnant women had higher holotranscobalamin (holoTC):total B~12~ ratios than non-pregnant, non-lactating controls, suggesting that such high intakes were required to provide sufficient supply to the developing fetus.[@R41] More research is required to decide on the upper limit of B~12~ intake in women before and during pregnancy, as higher B~12~ intake in the third trimester was positively associated with offspring birth weight in high-BMI women (who are already at high risk of having macrosomic babies), although circulating B~12~ levels were not reported here.[@R42] There is also no consistent evidence that increased B~12~ intake or supplementation is associated with reduction in the prevalence of subclinical B~12~ deficiency in adults (particularly neurocognitive decline in the elderly).[@R43] [@R44] Therefore, until the availability of further studies, our data call for revision of the UK RNI (and EAR) for B~12~ to be at least in line with the current European recommendations (4.5 μg/day).[@R24]

The estimated B~12~ intake in preconceptional or women in early pregnancy and specifically its relationship with serum levels has not been widely studied. In developing countries, over 50% of women of reproductive age do not meet the RNIs for B~12~[@R45] [@R46] and separate surveys from three developing countries (Turkey, Iran and China) found B~12~ deficiency rates of 21--23%.[@R47] An Australian study on young females found a similar rate to ours (11.4%), albeit using a lower threshold of 120 pmol/L.[@R50] As the B~12~ levels fall by around 10% from preconception to early pregnancy,[@R19] if we extrapolate our findings, the proportion of pregnant women with B~12~ levels below 150 pmol/L is likely to be much higher. More than a third of vegetarian/vegan women in our study had B~12~ deficiency, which was in keeping with studies from other UK adult population[@R51] and elsewhere.[@R52] Thus our findings highlight the need for specific advice for the vegetarian/vegan population about potential sources of B~12~, as well as recommending them to have their B~12~ levels checked (and corrected) if they are planning pregnancy.

Folate intake {#s4b}
-------------

Our study shows that consumption of dietary folate has fallen by around 14% in the 10 years between the two surveys and nearly 50% of women are now consuming below the UK RNI. The Scientific Advisory Committee on Nutrition within the UK Food Standards Agency has recommended mandatory folic acid fortification of food products to the UK DOH,[@R53] which, if implemented, would increase folate intake and consequently serum levels in the population as it did in the USA.[@R54] However, if mandatory fortification does occur, it is possible that improving folate levels can reduce B~12~ levels due to usage of the available B~12~.[@R55] In addition, B~12~ deficiency is the strongest driver of Hcy in a folate-replete population.[@R56] Therefore fortification of food products with B~12~ together with folate should be considered if there is to be a policy change in the UK or, as a minimum, B~12~ supplements recommended for women in the peri-conceptional period, especially if they are at high risk of deficiency.

The strengths of our study are that this is the first study of its kind from the UK to evaluate B~12~ and folate among women in the preconceptional stage. Extensive data on these women including anthropometry, biochemical markers and dietary information allowed comparison of intake and serum levels adjusted for possible confounders. There were three important limitations of this data set: (1) lack of sufficient biochemical data in the second survey, (2) lack of data on other biomarkers such as holoTC or MMA and (3) lack of haematological and clinical information relevant to the effects of B~12~. Since we were able to compare the nutrient intakes between the two cohorts, which was predictive of serum levels in the earlier survey, we believe that the availability of serum B~12~ in the latter cohort may not necessarily change the findings. Hcy is a readily available marker in clinical practice as opposed to holoTC and MMA. Therefore, our findings are applicable to wider clinical practice. Any future prospective studies involving preconceptional or pregnant women should include more clinical information as well as these biomarkers for a better evaluation of B~12~ status. In conclusion, our study supports revision of the UK RNI to at least match the European recommendations and also calls for assessing maternal B~12~ status in preconception or early pregnancy.
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